Safety and efficacy of a novel phytoceutical formulation CL18100F4 in increasing gut motility and improving stool consistency in animals

Jan 22, 2026Toxicology mechanisms and methods

Safety and effectiveness of a new plant-based treatment for improving gut movement and stool consistency in animals

AI simplified

Gut-Brain Axis on OpenScience ↗PubMed ↗DOI ↗

Abstract

Administration of CL18100F4 (200- and 300 mg/kg) resulted in significant improvements in gastric emptying (73.97 ± 15.12%) and intestinal transit (80.43 ± 4.76%) in Wistar rats.

CL18100F4, a polyherbal formulation, enhanced intestinal contractility in isolated rat ileum in a dose-dependent manner.
Muscarinic receptors were involved in the gastrokinetic effects of CL18100F4, as indicated by atropine inhibition.
Fecal moisture content increased significantly (57.42 ± 5.05%) with CL18100F4 treatment, while fecal pellet count remained unaffected.
Serum corticosterone levels decreased significantly, whereas serotonin levels increased, indicating modulation of the gut-brain axis.
No adverse effects were noted on liver, kidney, or metabolic parameters, suggesting a good safety profile for CL18100F4.

AI simplified

Constipation and gastrointestinal (GI) dysmotility are prevalent disorders often associated with impaired gut-brain axis regulation and limited therapeutic options. This study investigated the safety and gastrokinetic efficacy of CL18100F4 (Digexin), a standardized polyherbal formulation comprising extracts of(Ashwagandha) root and(Okra) pods.assays using isolated rat ileum demonstrated that CL18100F4 significantly enhanced intestinal contractility in a dose-dependent manner, with muscarinic receptor involvement confirmed by atropine inhibition.administration of CL18100F4 (200- and 300 mg/kg body weight for eight days) to Wistar rats showed significant improvements in gastric emptying (73.97 ± 15.12%, = 0.0410), intestinal transit (80.43 ± 4.76%, = 0.0184), and fecal moisture content (57.42 ± 5.05%, = 0.0101), without affecting fecal pellet count. Serum corticosterone levels were significantly reduced, while serotonin levels increased, suggesting modulation of the gut-brain axis. No adverse alterations were observed in liver, kidney, or metabolic biochemical parameters, indicating systemic safety. Collectively, these findings demonstrate that CL18100F4 exerts synergistic gastrokinetic and neuroendocrine regulatory effects while maintaining a good safety profile. The formulation shows promise as a functional food or nutraceutical for managing GI motility disorders by modulating the gut-brain axis-associated biomarkers. ® Withania somnifera Abelmoschus esculentus Ex vivo In vivo p p p

Full Text

Full text is available at the source.

View full text ↗

Safety and efficacy of a novel phytoceutical formulation CL18100F4 in increasing gut motility and improving stool consistency in animals

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the gut-brain axis brief